CN Patent

CN111620823A — 一种化合物的新型晶体及其制备方法

Assigned to Erjian Holding Co ltd · Expires 2020-09-04 · 6y expired

What this patent protects

本发明涉及5‑({[2‑氨基‑3‑(4‑氨甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1h‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的新型晶体和制备5‑({[2‑氨基‑3‑(4‑氨甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1h‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的两性离子的方法。

USPTO Abstract

本发明涉及5‑({[2‑氨基‑3‑(4‑氨甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1h‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的新型晶体和制备5‑({[2‑氨基‑3‑(4‑氨甲酰基‑2,6‑二甲基‑苯基)‑丙酰基]‑[1‑(4‑苯基‑1h‑咪唑‑2‑基)‑乙基]‑氨基}‑甲基)‑2‑甲氧基‑苯甲酸的两性离子的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111620823A
Jurisdiction
CN
Classification
—
Expires
2020-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Erjian Holding Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.